- Thu 04 May 2023
- nature
- Sara Reardon
Alzheimer’s drug donanemab: what promising trial means for treatments
Results suggest that the amyloid-targeting drug candidate slows cognitive decline in some people, but questions remain over its potential side effects.
Read more >>